Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

Innovative Medical

Status and phase: Completed; Phase 4

Conditions: Macula Thickening

Treatments: Drug: Gatifloxacin 0.3%; Drug: Prednisolone Acetate; Drug: Ketorolac 0.4%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00433225

5293

Details and patient eligibility

About

The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females > 50 years old
• Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
• Likely to complete all study visits and able to provide informed consent
• Visual potential of 20/25 or better

Exclusion criteria

• · Prior use of topical ketorolac

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies